Evidence map›Paper›PMID 27995994›Full record

ArticleScientific reports2016

Counteracting bone fragility with human amniotic mesenchymal stem cells.

Anna M Ranzoni, Michelangelo Corcelli, Kwan-Leong Hau, Jemma G Kerns, Maximilien Vanleene, Sandra Shefelbine, Gemma N Jones, Dafni Moschidou, Benan Dala-Ali, Allen E Goodship and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. New perspectives on the treatment of skeletal dysplasia.Therapeutic advances in endocrinology and metabolism · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Anna M RanzoniInstitute for Women's Health, University College London, London, UK.
Michelangelo CorcelliInstitute for Women's Health, University College London, London, UK.
Kwan-Leong HauInstitute for Women's Health, University College London, London, UK.
Jemma G KernsLancaster Medical School, Lancaster University, Lancaster, UK.
Maximilien VanleeneONCOLille, Regional University Hospital of Lille, Lille, France.
Sandra ShefelbineDepartment of Mechanical and Industrial Engineering, Northeastern University, Boston MA, USA.
Gemma N JonesInstitute of Reproduction and Developmental Biology, Imperial College London, London, UK.
Dafni MoschidouInstitute for Women's Health, University College London, London, UK.
Benan Dala-AliInstitute of Orthopaedics and Musculoskeletal Science, Royal National Orthopaedic Hospital, University College London, Stanmore, UK.
Allen E GoodshipInstitute of Orthopaedics and Musculoskeletal Science, Royal National Orthopaedic Hospital, University College London, Stanmore, UK.
Paolo De CoppiUCL Great Ormond Street Institute of Child Health, University College London, London, UK.
Timothy R ArnettDepartment of Cell &Developmental Biology, University College London, London, UK.
Pascale V GuillotInstitute for Women's Health, University College London, London, UK.
University College London · GBRoyal National Orthopaedic Hospital · GBImperial College London · GBLancaster University · GBLondon Women's Clinic · GBNortheastern University · US

Funding

Department of Health RP_2014-04-046
6 · The paper itself

Abstract

The impaired maturation of bone-forming osteoblasts results in reduced bone formation and subsequent bone weakening, which leads to a number of conditions such as osteogenesis imperfecta (OI). Transplantation of human fetal mesenchymal stem cells has been proposed as skeletal anabolic therapy to enhance bone formation, but the mechanisms underlying the contribution of the donor cells to bone health are poorly understood and require further elucidation. Here, we show that intraperitoneal injection of human amniotic mesenchymal stem cells (AFSCs) into a mouse model of OI (oim mice) reduced fracture susceptibility, increased bone strength, improved bone quality and micro-architecture, normalised bone remodelling and reduced TNFα and TGFβ sigalling. Donor cells engrafted into bones and differentiated into osteoblasts but importantly, also promoted endogenous osteogenesis and the maturation of resident osteoblasts. Together, these findings identify AFSC transplantation as a countermeasure to bone fragility. These data have wider implications for bone health and fracture reduction.

Indexed as

Mesenchymal Stem Cell TransplantationAmnionAnimalsBone and BonesBone RemodelingCell DifferentiationDisease Models, AnimalFemaleFlow CytometryFractures, BoneGene Expression ProfilingGenetic MarkersHumansMaleMesenchymal Stem CellsMiceGenetic MarkersTransforming Growth Factor betaTumor Necrosis Factor-alpha

Identifiers

PMID27995994
PMCPMC5171815
OpenAlexW2562890804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.